8 results about "Cellular Regulation" patented technology

The invention relates to a biological information data processing technology, in particular to a method for analyzing a single-cell Hi-C regulation scale chromatin band, which comprises the following steps: preprocessing single-cell Hi-C data to generate pseudo-batch Hi-C data; performing normalization processing on the pseudo batch Hi-C data to extract a Hi-C contact matrix of each chromosome; identifying and detecting false batch strips from the Hi-C contact matrix; projecting the pseudo batch strips to the original single cell Hi-C data to obtain single cell strips; and carrying out quantitative analysis on the single-cell strip in the original single-cell Hi-C data. According to the method, the regulation and control scale chromatin bands with definite endpoints and directivity can be stably identified, and a band set with remarkable statistics is output.

The present application relates to biological information data processing technology, and is a method for single-cell Hi-C regulatory scale chromatin band analysis, comprising the following steps: preprocessing single-cell Hi-C data to generate pseudo-bulk Hi-C data; normalizing the pseudo-bulk Hi-C data to extract the Hi-C contact matrix of each chromosome; identifying and detecting pseudo-bulk bands from the Hi-C contact matrix; projecting the pseudo-bulk bands onto the original single-cell Hi-C data to obtain single-cell bands; and quantitatively analyzing the single-cell bands in the original single-cell Hi-C data. The present application can stably identify regulatory scale chromatin bands with clear endpoints and directionality, and output statistically significant band sets.

This invention relates to a liposomal formulation based on myeloid cell regulation and chemotherapy enhancement, along with its preparation method and antitumor applications, belonging to the technical field of pharmaceutical formulations. The liposomal formulation uses liposomes as carriers to co-load the CD11b agonist leukadherin-1 (LA1) prodrug (DSPE-PEG2000-Azo-LA1) and the gemcitabine prodrug Gem-SS-Chol. DSPE-PEG2000-Azo-LA1 contains a hypoxia-responsive azobenzene linker, and Gem-SS-Chol contains a glutathione-responsive disulfide bond, enabling precise drug release within the tumor microenvironment. This formulation exhibits uniform particle size and good stability, synergistically exerting chemotherapeutic and immunomodulatory effects. It effectively inhibits the proliferation and migration of pancreatic cancer tumor cells, enhances tumor cell immunogenic cell death, regulates the phenotype of myeloid immune cells in the tumor immunosuppressive microenvironment, and improves the therapeutic effect of pancreatic cancer. This invention provides a novel and highly efficient liposomal formulation for pancreatic cancer treatment, focusing on myeloid cell regulation and chemotherapy enhancement.

This invention relates to the field of cell regulation technology and discloses a multi-parameter feedback-based intelligent regulation method for Chir99021-induced differentiation of dental pulp stem cells. The method includes: acquiring a dataset of the differentiation process of dental pulp stem cells and performing structured analysis to obtain a multi-parameter monitoring dataset; performing multi-dimensional assessment of cell differentiation status to obtain a differentiation status assessment characterization; obtaining drug release regulation parameters based on the differentiation status assessment characterization and historical differentiation trend data; performing multi-dimensional planning on the differentiation status assessment characterization and drug release regulation parameters to obtain a regulation strategy, and encoding and reconstructing the regulation strategy to obtain microenvironment regulation instructions; applying the microenvironment regulation instructions to obtain an optimized culture microenvironment and monitoring cell state information in the optimized culture microenvironment; and iteratively regulating the drug release regulation parameters based on the cell state information to obtain the final regulation instructions. This invention can improve the accuracy of Chir99021-induced differentiation regulation of dental pulp stem cells.

The method of generating multipotent stem cells is a method for producing and / or expanding multipotent stem cells by delivering at least one reprogramming protein into somatic cells. The at least one reprogramming protein includes a Master Regulator (MR) protein, which may be BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, or FLI1. The bromodomain protein BAZ2B, in particular, was identified by first generating bi-species heterokaryons by fusing Tcf7l1− / − murine embryonic stem cells (ESCs) with human B-cell lymphocytes. Reprogramming of the B-cell nuclei to a multipotent state was tracked by human mRNA transcript profiling at multiple timepoints. Interrogation of a human B-cell regulatory network with gene expression signatures collected from such reprogramming time series identified eight candidate Master Regulator proteins, which were validated in human cord blood-derived hematopoietic progenitor and lineage-committed cells.

The invention discloses a system and a method for realizing cell regulation and control based on luminous oscillation stimulation of cell nucleuses, and relates to the technical field of crossing of biotechnology and optical micro-control. The method comprises the following steps: internalizing biocompatible microspheres beside a living cell nucleus, capturing the microspheres by using an optical tweezers module, and driving a light potential well to carry out double-position high-speed alternate switching by using a parameter control unit, so as to construct a programmable optical mechanical oscillator to apply oscillation stimulation to cells in a set direction, frequency and amplitude. According to the invention, the limitation of the traditional method is broken through, and direct and controllable mechanical stimulation and observation on the cell nucleus in the living cell are realized.

The application relates to the technical field of biomaterials, in particular to a stem cell aggregate-derived decellular extracellular matrix and application thereof in bone defect repair. The decellular extracellular matrix is formed by subjecting a 3D cell aggregate in the form of a sphere to decellularization treatment, and the 3D cell aggregate is induced to form by transferring adult bone marrow mesenchymal stem cells after culture to a low-absorption cell culture carrier. The 3D dECM has a complete three-dimensional scaffold structure and abundant pores, while retaining key extracellular matrix components such as collagen, fibronectin and laminin, and is closer to the in-vivo tissue microenvironment; the 3D dECM significantly enhances the migration ability of cells, effectively improves the stemness of BMSCs, promotes extracellular matrix synthesis, and improves the mitochondrial function of BMSCs, has excellent cell regulation ability and functional activity, and thus solves the problems of low bioactivity and insufficient bionics of traditional 2D dECM.

The invention belongs to the technical field of biological medicines, and discloses an immunoregulation method for directional differentiation of CD4 + T cells. According to the method, an intelligent response type three-dimensional support composed of a temperature-sensitive block copolymer, MMP degradable peptide and a pH-sensitive component is constructed, a space-time nest is formed in situ at a focus, three active molecules including vorinostat, IL-6 / rapamycin and TGF-beta1 / retinoic acid are loaded by adopting a layered drug loading strategy, dynamic release is performed according to a microenvironment, and the pH-sensitive drug-loaded vorinostat / IL-6 / rapamycin / TGF-beta1 / retinoic acid is obtained. The efficient, lasting and antigen-specific directional induction of CD4 + T cells to subgroups such as Treg or Th17 is realized. The method is not only suitable for various disease scenes such as tumors, autoimmune diseases and chronic inflammation, but also can flexibly adapt to different T cell subpopulation induction requirements by replacing loaded bioactive molecule combinations and antigen peptide sequences, the local T cell regulation efficiency can be remarkably improved, systemic toxicity is avoided, and the method is suitable for clinical application. And good biocompatibility and clinical transformation potential are achieved.